Detail akcie INFLARX NV online

Business Summary: Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Inflarx NV revenues decreased from EUR36K to EUR0K. Net loss decreased 14% to EUR8.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Other financial result increase from EUR103K to EUR6.1M (income), Other income increase from EUR36K to EUR541K (income), Research and development expenses decrease of 4% to EUR7M (expense).